Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab plus topical corticosteroids in children with moderate-to-severe atopic dermatitis
NL-OMON59282Phase 3Active, not recruiting
- Sponsor
- LEO Pharma
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Tralokinumab + topical corticosteroids with Placebo + topical corticosteroids (2 arms). Primary endpoints: IGA 0/1 at Week 16 and EASI75 at Week 16. Started May 2025; status: active, not recruiting.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON59282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59282.